Optimising MS disease-modifying therapies: Antibodies in perspective

Journal of Neurology, Supplement

Volumn 251, Issue 5, 2004, Pages

  Giovannoni, Gavin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Glatiramer acetate; Immune tolerance; Interferon ; Multiple sclerosis; Neutralising antibodies

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8; GLATIRAMER; INSULIN; INTERFERON ANTIBODY; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

CONFERENCE PAPER; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERANCE; ERYTHROCYTE APLASIA; GLYCOSYLATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ANTIBODIES; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 5644285449     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1505-x     Document Type: Conference Paper

References (33)

1. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-462
2. rd, Deisenhammer F (2002) Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73: 465-469
3. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628-1636
4. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
5. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
6. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889-894
7. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K and the Danish Multiple Sclerosis Study Group (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48:706-712
8. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW and the International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23
9. Salama HH, Hong J, Zang YC, El-Mongui A, Zhang J (2003) Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 126: 2638-2647
10. Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE (1998) A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 18:1025-1030
11. WHO Expert Committee on Biological Standardisation (1985) Thirty-fifth report. WHO Technical Report Series 725. World Health Organisation, Geneva
12. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N and the Danish Multiple Sclerosis Study Group (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
13. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, Antonelli G (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3-8
14. Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F (2003) Interferon-beta: the neutralizing antibody (NAb) titer predicts reversion to NAb negativity. Mult Scler 9(Suppl 9):P482. S119
15. Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G (2003) Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74:946-949
16. van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L (2000) Contrasting responses to interferon beta-lb treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 48:313-322
17. Petereit HF, Nolden S, Schoppe S, Bamborschke S, Pukrop R, Heiss WD (2002) Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 8:492-494
18. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundstrom E, Ehrlich S, Wernecke KD, Volk HD, Zipp F (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361: 2036-2043
19. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
20. Villoslada P, Barcellos LF, Rio J, Begovich AB, Tintore M, Sastre-Garriga J, Baranzini SE, Casquero P, Hauser SL, Montalban X, Oksenberg JR (2002) The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 130: 194-201
21. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59:1496-1506
22. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M and the Independent Comparison of Interferon (INCOMIN) Trial Study Group (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
23. Eckardt KU, Casadevall N (2003) Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18:865-869
24. Casadevall N (2002) Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 17 (Suppl 5):42-47
25. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73: 148-153
26. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608
27. Ingerslev J (2000) Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 85(10 Suppl): 15-20
28. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C (2002) Monthly corticosteroids decrease neutralizing antibodies to IFN beta1b: a randomized trial in multiple sclerosis. J Neurol 249: 50-56
29. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Rickert JR, Rudick RA, Wauhant EL, Weinstock-Guttman B, Scaramucci JO, Burnett BK, Jones WE, Simonian NA (1999). Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 2:1-6
30. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P (2001) Interferon-beta (IFN-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56-61
31. Giovannoni G (2003) Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 61(9 Suppl 5):S13-S17
32. Ure DR, Rodriguez M (2002) Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 16:1260-1262
33. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R (2003) Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 9:592-599